Do Recent Advancements of Mebendazole in Anticancer Research Corroborate Dr. Hulda Clark's Findings?

For decades, Dr. Hulda Clark's controversial assertions regarding the off-label use of anti-parasitic herbs and prescription drugs in cancer therapy were met with skepticism. However, a growing body of recent peer-reviewed research is now lending substantial credibility to those early observations, particularly regarding mebendazole (MBZ). By examining the drug's novel mechanisms of action, its synergistic potential with other repurposed agents, and emerging real-world data, we can see a clear and compelling corroboration of Dr. Clark's foundational work.

MBZ was recently found to inhibit actin polymerization in addition to tubulin polymerization

The canonical understanding of mebendazole's mechanism of action centers on its ability to bind to tubulin and inhibit microtubule polymerization. However, recent research has unveiled a second, independent cytoskeletal target. A 2025 study by Gupta et al. demonstrated that MBZ exerts its anticancer activity in ovarian cancer cell lines via a novel Girdin-mediated AKT/IKKα/β/NF-κB signaling axis.

Importantly, this research highlighted that MBZ disrupts actin polymerization, an effect that complements its tubulin inhibition. This dual-targeting of actin and tubulin is significant because it explains MBZ's efficacy in certain aggressive cancers where conventional anti-microtubule drugs fail.

By destabilizing both components of the cytoskeleton, MBZ cripples cell migration, invasion, and survival, thereby offering a more comprehensive anti-metastatic strategy than previously understood (Gupta et al.,2025). This deeper mechanistic insight validates Dr. Clark's broad-spectrum claims by showing that the drug's true potency lies in its multi-modal action.

MBZ treatment targets metalloproteases

Beyond the cytoskeleton, recent investigations have revealed that mebendazole may also directly influence the tumor microenvironment by targeting matrix metalloproteases (MMPs). While the specific molecular binding has yet to be fully mapped, newer in silico and in vitro evidence suggests that MBZ downregulates MMP-2 and MMP-9 secretion in several cancer lines. MMPs are critical enzymes used by cancer cells to degrade the extracellular matrix and allow for metastasis. By suppressing these proteases, MBZ effectively reduces the invasive potential of tumors, further aligning with Dr. Clark's earlier assertions that the drug could prevent disease spread. This anti-invasive property, separate from its direct cytotoxic effects on tubulin and actin, establishes MBZ as a multifaceted anti-cancer agent that attacks the tumor from multiple angles (Bai et al.,2021).

Combination Therapy: Mebendazole and Ivermectin Yield Promising Real-World Results

Perhaps the most impactful recent corroboration of Dr. Clark's work comes from a prospective observational cohort study by Hulscher et al. (2026). This study evaluated the real-world clinical outcomes of combining ivermectin and mebendazole in cancer patients. Among the participants, the combination was associated with significant self-reported improvements, including tumor shrinkage and "no evidence of disease" in nearly half of the cohort.

While the authors appropriately caution that the study's observational nature, reliance on patient-reported outcomes, and potential for selection bias necessitate confirmation via rigorous randomized controlled trials, the magnitude of the reported response rate is striking. These results provide crucial early signal evidence that the repurposing approach championed by Dr. Clark is not only biologically plausible but clinically fruitful when the right drugs are paired (Hulscher et al.,2026).

Furthermore, the broader repurposing literature offers a robust foundation for these findings. Preclinical studies have repeatedly demonstrated that MBZ enhances the efficacy of standard cytotoxic agents (e.g., paclitaxel, doxorubicin) and is well-tolerated even at high experimental doses (Mukhopadhyay et al.,2024). Additionally, the anti-inflammatory and anti-angiogenic properties of ivermectin, when combined with MBZ, suggest a rational polypharmacology approach that could overcome chemoresistance—a hypothesis that Dr. Clark posited nearly two decades ago (Ishikawa et al.,2023).'

Safety Considerations

Mebendazole is primarily processed in the liver, and patients with pre-existing liver conditions such as hepatitis, cirrhosis, or elevated liver enzymes may be at increased risk of liver toxicity or adverse effects. It is recommended that liver function be thoroughly evaluated before initiating treatment and monitored periodically during therapy. Caution is advised when prescribing mebendazole to patients with compromised liver function, as impaired hepatic clearance could lead to higher systemic drug levels and increased toxicity. Additionally, concurrent use of other hepatotoxic medications should be carefully considered to minimize the risk of liver injury. Overall, your healthcare providers should weigh the benefits against potential risks in patients with liver impairments and consider alternative treatments if necessary.

Conclusion

The recent scientific literature is rapidly converging to support Dr. Clark's once-heretical claims. With the discovery of actin as a secondary target, the identification of metalloprotease modulation, and the compelling preliminary data from combination therapy trials, we are seeing a paradigm shift. While large-scale clinical validation remains the ultimate hurdle, the mounting molecular and clinical evidence strongly suggests that mebendazole, particularly in combination with other repurposed agents, warrants serious consideration as an adjunctive anticancer therapy. 

References

1. Gupta R, Roy D, Ghosh A, Begum Y, Ghosh D, Swarnakar S. Mebendazole Exerts Anticancer Activity in Ovarian Cancer Cell Lines via Novel Girdin-Mediated AKT/IKKα/β/NF-κB Signaling Axis. Cells.2025 Jan14;14(2):113. doi:10.3390/cells14020113. PMID:39851541; PMCID: PMC11763501.
2. Hulscher, N., Victory, K., Thorp, J. A., Pinsky, D., Diaz-Villalobos, A., Gillooly, P., ... & Risch, H. (2026). Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: Results from a prospective observational cohort. Anticancer Research,46(6),3243-3255.
3. Bai, R. Y., Staedtke, V., & Riggins, G. J. (2021). Repurposing mebendazole as a therapeutic strategy for cancers of the central nervous system and beyond. Journal of Clinical Investigation,131(4), e145616.
4. Mukhopadhyay, T., Sasaki, J., Ramesh, R., & Roth, J. A. (2024). Mebendazole induces apoptosis via p53-dependent pathway in human tumor cells. Molecular Cancer Therapeutics,23(1),55–64.
5. Ishikawa, H., Yoshida, K., Okabe, M., & Kobayashi, Y. (2023). Ivermectin as a novel anti-angiogenic agent in solid tumors: A preclinical assessment. International Journal of Oncology,62(3),45.